Article

Acquired resistance to PD-L1 inhibition is associated with an enhanced type I IFN-stimulated secretory program in tumor cells

2021-07-01

Abstract excerpt

<h4>Background</h4> Interferon (IFN) pathway activation in tumors can have dual, sometimes opposing, influences on immune responses. Therapeutic inhibition of programmed cell death ligand (PD-L1) – a treatment that reverses PD-1-mediated suppression of tumor-killing T-cells - is linked to alterations in IFN signaling; however, less is known about the role of IFNs after treatment resistance. Since IFN-regulated in...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c4dc2d32-7a72-5d2f-a456-d542fd4d9636
DOI: 10.1101/2021.07.01.450417

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Acquired resistance to PD-L1 inhibition is associated with an enhanced type I IFN-stimulated secretory program in tumor cellsDOI 10.1101/2021.07.01.450417Read

Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-γ-signaling mutant cancer cells.Semantic proximity Read

CAR Triggered Release of Type-1 Interferon Limits CAR T-Cell Activities by an Artificial Negative Autocrine LoopSemantic proximity Read

Investigating Mechanisms of Response or Resistance to Immune Checkpoint Inhibitors by Analyzing Cell-Cell Communications in Tumors Before and After Programmed Cell Death-1 (PD-1) Targeted Therapy: An Integrative Analysis Using Single-cell RNA and Bulk-RNA Sequencing DataSemantic proximity Read

Transcriptomic Integration Reveals a Conserved Inflammatory–Proliferative Paradox in Acquired Resistance to Immune Checkpoint BlockadeSemantic proximity Read

Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancerSemantic proximity Read

Tumour cells can escape antiproliferative pressure by interferon-β through immunoediting of interferon receptor expressionSemantic proximity Read

Signaling by Type I Interferons in Immune Cells: Disease ConsequencesSemantic proximity Read

Genetic Dysregulation of Immunologic and Oncogenic Signaling Pathways Associated with Tumor-intrinsic Immune Resistance: A Molecular Basis for Combination Targeted Therapy-Immunotherapy for CancerSemantic proximity Read

Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1BSemantic proximity Read

Targeting Interferon-Driven Inflammatory Memory Prevents Epigenetic Evolution of Cancer Immunotherapy ResistanceSemantic proximity Read

An experimental model of anti-PD-1 resistance exhibits activation of TGFß and Notch pathways and is sensitive to local mRNA immunotherapySemantic proximity Read

Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implicationsSemantic proximity Read